This warrants further clinical studies of this new combination therapy combining an antigen-presenting cell activator with an immune checkpoint inhibitor.Ĭombinatorial approaches that target multiple aspects of the cancer immunity cycle, 1 including APC activation, are promising strategies for the treatment of cancer.

Treatment induced an increase in activated CD8 and CD4 T cell counts, and in some of the soluble biomarkers, particularly interferon (IFN)-, a Th1 signature cytokine.Īn overall response rate (ORR) of 33 was observed in patients partly with pembrolizumab-refractory of part A and ORR of 50 was observed in patients with PD-1 nave of part B.Ĭonclusions Efti was well tolerated in combination with pembrolizumab with encouraging antitumor activity. Sustained systemic exposure to the product was obtained in all patients following s.c.

No dose-limiting toxicities were reported and the main adverse event for efti was injection site reactions. Results Twenty-four patients with melanoma received pembrolizumab and bi-weekly subcutaneous (s.c.) injections of efti at doses 1 mg, 6 mg or 30 mginjection for up to 6 months (part A) or 30 mginjection for up 12 months (part B).

Software Lag Switch 1.2 Plus The Standard.

Software Lag Switch 1.2 Trial Is Testing.

Software lag switch 1.2 tpb